EXERCISING TOGETHER for Couples Coping With Cancer

Sponsor
OHSU Knight Cancer Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT03630354
Collaborator
National Cancer Institute (NCI) (NIH), Oregon Health and Science University (Other)
588
1
3
56.4
10.4

Study Details

Study Description

Brief Summary

The Exercising Together trial is a single-blind, parallel group, randomized controlled trial comparing 3 arms: Arm 1 (experimental): Exercising Together where couples perform partnered exercise in a supervised, group setting versus two comparator conditions where survivors and partners perform exercise routines separately in either a supervised group setting (Arm 2) or unsupervised at home (Arm 3). All three arms will train for a 6-month period and then be followed 6 months later. Data will be collected at baseline, 3, 6 and 12 months.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Exercise Intervention
  • Behavioral: Exercise Intervention
  • Other: Informational Intervention
  • Other: Questionnaire Administration
N/A

Detailed Description

PRIMARY OBJECTIVES:
  1. Determine the efficacy of Exercising Together on relationship quality (intimacy, communication and incongruence) in couples coping with prostate cancer (PC), breast cancer (BC), or colorectal cancer (CRC).

  2. Determine the efficacy of Exercising Together on the physical health (body composition, lipids, insulin resistance, blood pressure, inflammation, and physical function) and mental health (anxiety, depressive symptoms, fear of recurrence) of both the survivor and spouse/partner.

  3. Determine how long individual and couple-level benefits from Exercising Together last.

EXPLORATORY OBJECTIVE:
  1. Identify the types of couples that benefit most from Exercising Together.

OUTLINE: Study is a 3-group, 12-month (6 months of exercise training + 6-months follow-up) randomized trial.

ARM I: Exercising Together Program: Couples perform partnered exercise over 1 hour, 2 days per week in a supervised, group setting.

ARM II: Exercising Together Program: Couples perform partnered exercise over 1 hour, 2 days per week in a supervised, group setting

ARM III: Survivors and partners undergo 2 training sessions over 1 hour with an exercise trainer and then perform exercise routines over 1 hour 2 days per week separately unsupervised at home or a facility following an instructional digital video disc (DVD).

The basic training program for all three study arms is a functional strength training program. Participants will use free weights (weighted vest, dumbbells, elastic bands) while performing lower body (chair rises, squats, lunges, stepups) and upper body (1-arm row, bench press, push-ups, triceps extension, bicep curls, shoulder raise) resistance exercise. Volume of resistance exercise, determined by intensity (weight, tailored to each individual) and duration (number of repetitions and sets), is gradually increased from low weight and high repetitions to more weight and fewer repetitions over the training period.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
588 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Supportive Care
Official Title:
EXERCISING TOGETHER © for Couples Coping With Cancer
Actual Study Start Date :
Jan 18, 2019
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm I (supervised exercise together)

Couples perform partnered exercise over 1 hour, 2 days per week in a supervised, group setting remotely for 6 months.

Behavioral: Exercise Intervention
Complete supervised exercise

Other: Questionnaire Administration
Ancillary studies

Experimental: Arm II (supervised exercise separately)

Survivors and partners perform exercise routines over 1 hour, 2 days per week separately in a supervised group setting remotely for 6 months.

Behavioral: Exercise Intervention
Complete supervised exercise

Other: Questionnaire Administration
Ancillary studies

Experimental: Arm III (unsupervised exercise separately)

Survivors and partners undergo 2 training sessions remotely over 1 hour with an exercise trainer and then perform exercise routines over 1 hour, 2 days per week unsupervised at home or a facility following an instructional DVD.

Behavioral: Exercise Intervention
Complete unsupervised exercise

Other: Informational Intervention
Receive instructional DVD

Other: Questionnaire Administration
Ancillary studies

Outcome Measures

Primary Outcome Measures

  1. Dyadic coping [Baseline (just prior to randomization), 3, 6 and 12 months]

    Measured by the Relationship Focused Coping Scale to assess the degree with which couples practice active engagement and protective buffering using questions on a scale from 1 (never) to 5 (very often).

  2. Emotional intimacy [Baseline, 3, 6 and 12 months]

    Measured by the Dyadic Adjustment Scale (DAS) to assess each partner's satisfaction with their relationship by answering questions on a 6-point scale ranging from 1(always agree) to 6 (always disagree).

  3. Physical intimacy [Baseline, 3, 6 and 12 months]

    Measured by the Physical Intimacy Behavior scale which asks participants the frequency that they engage in, initiate, and avoid intimate behaviors using questions on scale from 1 (none of the time) to 4 (most or all of the time).

  4. Concealment of symptoms [Baseline, 3, 6 and 12 months]

    Measured by the Emotional-Intimacy Disruptive Behavior Scale. Patients report the extent to which they engage in 8 behaviors using a scale from 1 (rarely or none of the time) to 4 (most or all of the time).

  5. Pain incongruence [Baseline, 3, 6 and 12 months]

    Measured by the degree of agreement between the survivor and partner ratings of the survivor's pain using the Brief Pain Inventory (BPI). This instrument has 2 subscales, pain intensity and pain interference. Values from items within each subscale are averaged together to yield scores 0-10. Low values indicate "no pain" and high values represent "pain as bad as you can imagine".

  6. Fatigue incongruence [Baseline, 3, 6 and 12 months]

    Measured by the degree of agreement between the survivor and partner ratings of the survivor's fatigue in the past 7 days using the Functional Assessment in Chronic Illness Therapy (FACIT) fatigue questionnaire. This instrument has 13 items, and possible scores from 0 to 52. Low values indicate no fatigue, while high values indicate high fatigue.

  7. Perceived physical function incongruence [Baseline, 3, 6 and 12 months]

    Measured by the degree of agreement between the survivor and partner ratings of the survivor's physical function in the past 4 weeks using the perceived physical function subscale of the SF-36 medical outcomes survey. Possible scores range from 0-100. Low scores indicate a high degree of limitation in performing physical activities, whereas high scores represent no limitations in performing physical activities due to health.

Secondary Outcome Measures

  1. Body composition [Baseline, 3, 6 and 12 months]

    Measured by bone-free lean and fat mass (kg) for the whole body determined from a whole body dual energy x-ray absorptiometry (DXA) (Hologic-QDR Discovery Wi; APEX software, v.4.02) scan.

  2. Cardiovascular health: serum fasting lipids [Baseline, 3, 6 and 12 months]

    Measured by serum fasting lipids (total, high-density and low-density lipoprotein cholesterol and triglycerides).

  3. Cardiovascular health: insulin resistance [Baseline, 3, 6 and 12 months]

    Measured by Homeostasis Model Assessment - Insulin Resistance - HOMA-IR: as the product of glucose and insulin, obtained from a fasting blood sample, divided by a constant.

  4. Cardiovascular health: resting blood pressure [Baseline, 3, 6 and 12 months]

    Measured by the average of three consecutive resting blood pressure measurements (systolic and diastolic pressures).

  5. Inflammation-hsCRP [Baseline, 3, 6 and 12 months]

    Measured by serum levels of high sensitivity C-reactive protein (hsCRP) obtained from a fasting blood sample.

  6. Inflammation-TNF alpha [Baseline, 3, 6 and 12 months]

    Measured by serum levels of tumor necrosis factor alpha (TNF alpha) obtained from a fasting blood sample.

  7. Objective physical function [Baseline, 3, 6 and 12 months]

    Measured by the Physical Performance Battery (PPB) to determine a person's ability to perform daily tasks independently. The PPB consists of 3 timed tests: 5 repeated chair stands, standing balance, and gait speed over 4 meters. Each test is scored 0 (unable) to 4 (completes without difficulty), based on quartiles of performance, then scores are summed. The possible range of scores is 0-12.

  8. Quality of life (QOL): QLQ-C30 [Baseline, 3, 6 and 12 months]

    Measures QOL in cancer patients including subscales of physical and mental functioning. Scores range from 0-100 for overall QOL and subscales where higher scores indicate better functioning.

  9. Quality of life (QOL): SF-36 [Baseline, 3, 6 and 12 months]

    The SF-36 measures quality of life using 8 subscales: perceived physical function, role limitations due to physical problems, social functioning, bodily pain, general mental health, role limitations due to emotional problems, vitality, and general health perceptions. All subscales have possible scores from 0-100, with items from each subscale averaged together. Low scores indicate worse QOL, while higher scores indicate better QOL.

  10. Depressive symptoms: CES-D [Baseline, 3, 6 and 12 months]

    Measured by the Center for Epidemiological Studies-Depression (CES-D) scale to determine the degree of depressive symptoms. Scores range from 0-60, with higher scores indicating more symptoms that occur at higher frequencies.

  11. Anxiety: PROMIS anxiety short form [Baseline, 3, 6 and 12 months]

    Measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety short form using questions on a scale ranging from 1 (never) to 5 (always).

  12. Fear of recurrence [Baseline, 3, 6 and 12 months]

    Measured by the Fear of Recurrence scale to assess the amount of concern survivors have about their cancer returning in the future. Participants respond to questions ranging from 1 (strongly agree) to 5 (strongly disagree).

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • SURVIVORS ONLY:

  • Histologically confirmed PC, BC or CRC without evidence of metastatic disease (confirmed by self-report on Health History Questionnaire. In the case a participant isn't able to confirm this criterion, a letter will be sent to his or her physician)

  • Three years or less from diagnosis date, by month and year, at time of enrollment (confirmed by self-report on Health History Questionnaire. In the case a participant isn't able to confirm this criterion, a letter will be sent to his or her physician)

  • Completed treatment (e.g., surgery, radiation and/or chemotherapy) >= 6 weeks prior to enrollment. Concurrent adjuvant hormone therapy is permitted and must have been initiated >= 6 weeks prior to enrollment. For prostate cancer, androgen deprivation therapy (ADT) may constitute primary treatment and must have been initiated >= 6 weeks prior to enrollment. For breast cancer, hormone therapy may constitute primary treatment and must have been initiated >= 6 weeks prior to enrollment. (confirmed by self-report on Health History Questionnaire. In the case a participant isn't able to confirm this criterion, a letter will be sent to his or her physician)

  • Co-residing with an intimate partner or spouse who is willing to participate (confirmed by self-report on Health History Questionnaire)

  • SURVIVORS AND SPOUSES/PARTNERS:

  • Underactive (< 2 strength training sessions per week, lasting 30 minutes or more per session, at a moderate intensity in the last month) (confirmed by self-report on Health History Questionnaire or by discretion of the principal investigator)

Exclusion Criteria:
  • SURVIVORS AND SPOUSES/PARTNERS

  • Cognitive difficulties that preclude answering the survey questions, participating in the exercise classes or performance tests, or providing informed consent as determined by the professional opinion of the principal investigator, Dr. Kerri Winters-Stone

  • A medical condition, movement or neurological disorder, or medication use that contraindicates participation in moderate intensity exercise. Specific contraindications include the following: declared pregnancy, poorly controlled diabetes, recent cardiac event, neuromuscular disease, untreated orthostatic hypertension, recent surgery, acute hernia, acute rheumatoid arthritis, severe memory disorders, severe balance disorder, inability to ambulate (use of an assistive device permitted), inability to stand for 3 minutes, severe hearing or vision problem. (For Survivor: Confirmed by physician clearance; For Spouse/Partner: must answer 'No' to American College of Sports Medicine pre-participation screening questions. If spouse/partner answers 'Yes' to either question they will be considered eligible upon physician clearance. Physician clearance may also be requested at the discretion of the principal investigator. For either: absence of pregnancy in persons who could possibly be pregnant but have not declared a pregnancy at screening, will be further screened with a pregnancy test administered at each testing visit.)

  • Knowingly unable to attend > 75% of the intervention classes due to conflict with the designated time of day, days of the week, and/or location for the exercise class which they initially enrolled. (Confirmed by documentation in the Case Report Form titled "CRF - Participant Contact Info_Exercising Together")

  • Not fluent in English and therefore incapable of answering survey questions, participating in class, following directions during performance testing, and providing informed consent when English is the language used. (Confirmed by documentation in the Case Report Form titled "CRF - Participant Contact Info_Exercising Together" or the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone.)

Contacts and Locations

Locations

Site City State Country Postal Code
1 OHSU Knight Cancer Institute Portland Oregon United States 97239

Sponsors and Collaborators

  • OHSU Knight Cancer Institute
  • National Cancer Institute (NCI)
  • Oregon Health and Science University

Investigators

  • Principal Investigator: Kerri Winters-Stone, OHSU Knight Cancer Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kerri Winters, Principal Investigator, OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier:
NCT03630354
Other Study ID Numbers:
  • STUDY00018000
  • NCI-2018-01404
  • STUDY00018000
  • R01CA218093
First Posted:
Aug 14, 2018
Last Update Posted:
May 23, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 23, 2022